



Making cardiac PET accessible to more people

PET is the most effective form of MPI for detecting CAD.¹⁻⁴ Now, with Flyrcado, you gain the flexibility of the longest available half-life of any cardiac PET tracer.^{1,4-6} Proven to provide accuracy over SPECT, Flyrcado creates more access to advanced cardiac imaging.⁴⁻⁸

Flyrcado brings operational flexibility:

- No need for onsite or mobile generators or cyclotrons^{1,4,5}
- Deliveries of on-demand unit doses up to five days a week⁶
- A 109-minute half-life that allows exercise stress imaging^{4,6}



Flyrcado combines precision with flexibility to serve care teams and patients alike



Versatile protocols due to longer half-life^{1,4,6}



Superior image quality compared to SPECT^{5,6}



Shorter positron range yields excellent resolution⁵



Supports pharmacologic & exercise stress⁶



Convenience of unit dose delivered from local pharmacy^{5,9}

“A game changer.”

—Flyrcado clinical trials principal investigator Jamshid Maddahi, MD, FACC, MASNC, UCLA School of Medicine, director, Biomedical Imaging Institute

With Flyrcado, cardiac imaging centers of all sizes and locations can offer cardiac PET to their patients.

Please see page 2 for Flyrcado Important Safety Information along with a QR code to the full Prescribing Information.



GE HealthCare

When is Flyrcado coming your way?

Availability of Flyrcado is expanding across the U.S. through GE HealthCare's contract manufacturing organization's partner network.

GE HealthCare is here to support your imaging center and network prepare to open the door to cardiac PET at your site of care with Flyrcado Forward, a program of learning opportunities and resources.



Be Flyrcado Forward

Sign up now for continued guidance and resources to expand access to cardiac PET for your patients.

Important Safety Information

Indications and Usage

FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

Contraindications

None

Warnings and Precautions

Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent's prescribing information.

REFERENCES: 1. Driessen RS, Raijmakers PG, Stuijzand WJ, Knaapen P. Myocardial perfusion imaging with PET. *Int J Cardiovasc Imaging*. 2017;33(7):1021-1031. 2. Schindler TH, Bateman TM, Berman DS, et al. Appropriate use criteria for PET myocardial perfusion imaging. *J Nucl Med*. 2020;61(8):1221-1265. 3. Liga R, Neglia D. Emerging F-18-labelled PET myocardial perfusion tracers. *Curr Cardiol Rep*. 2020;22(10):116. 4. Patel KK, Singh A, Bateman TM. The potential of F-18 flurpiridaz PET/CT myocardial perfusion imaging for precision imaging. *Curr Cardiol Rep*. 2022;24(8):987-994. 5. Maddahi J, Packard RRS. Cardiac PET perfusion tracers: current status and future directions. *Semin Nucl Med*. 2014;44(5):333-343. 6. Flyrcado (flurpiridaz F 18 injection). Full Prescribing Information. Marlborough, MA: GE HealthCare. 7. Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET Myocardial perfusion imaging in patients with suspected coronary artery disease. *J Am Coll Cardiol*. 2023;82(16):1598-1610. 8. Bourque JM. Cardiac PET perfusion imaging: AURORA lights the way to a new era. *J Am Coll Cardiol*. 2023;82(16):1611-1613. 9. Iskandrian AE, Dilsizian V, Garcia EV, et al. Myocardial perfusion imaging: lessons learned and work to be doneupdate. *J Nucl Cardiol*. 2018;25(1):39-52.

Radiation risks: FLYRCADO contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.

Adverse Reactions

Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence $\geq 2\%$) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at GPV.drugsafety@gehealthcare.com or FDA at 800-FDA-1088 or www.fda.gov/medwatch

© 2025 GE HealthCare
Flyrcado is a trademark of GE HealthCare.
GE is a trademark of General Electric
Company used under trademark license.
March 2025 | JB11489US



Visit [gehealthcare.com/flyrcado-pi](https://www.gehealthcare.com/flyrcado-pi)
for full Prescribing Information



GE HealthCare